24 studies found for:    MACULAR DEGENERATION, AGE-RELATED, 6
Show Display Options
Rank Status Study
1 Completed Safety And Tolerability Study Of RN6G In Patients With Dry, Age-Related Macular Degeneration
Conditions: Age-Related Maculopathy;   Age-Related Maculopathies;   Eye Diseases;   Retinal Degeneration;   Macular Degeneration
Interventions: Biological: RN6G;   Biological: Placebo
2 Completed Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy
Conditions: Age-Related Maculopathy;   Age-Related Maculopathies;   Eye Diseases;   Retinal Degeneration;   Macular Degeneration
Interventions: Biological: RN6G;   Biological: Placebo
3 Recruiting Omega 6:Omega 3 Ratio and Progression of Age-related Macular Degeneration (AMD).
Condition: Age-related Macular Degeneration
Intervention:
4 Terminated Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration
Condition: Age-Related Maculopathy
Interventions: Biological: RN6G;   Biological: Placebo
5 Unknown  A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD
Condition: Age-Related Macular Degeneration (AMD)
Intervention: Drug: pegaptanib sodium (Macugen)
6 Completed Study of the Safety, Tolerability and Pharmacokinetics of 1 Mg/Eye and 3 Mg/Eye Pegaptanib Sodium in Patients With Exudative Age-Related Macular Degeneration (AMD)
Condition: Age-Related Macular Degeneration
Intervention: Drug: pegaptanib sodium (Macugen)
7 Completed Safety and Tolerability of an Intravenous Infusion of ACZ885 in Patients With Wet Age-Related Macular Degeneration
Condition: Wet Age-Related Macular Degeneration
Intervention: Drug: ACZ885
8 Terminated Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)
Condition: Age-Related Macular Degeneration
Interventions: Drug: Photodynamic Therapy (PDT) with Visudyne (verteporfin);   Drug: Macugen (pegaptanib sodium)
9 Completed Intravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related Macular Degeneration (AMD)
Condition: Macular Degeneration
Intervention: Drug: pegaptanib sodium
10 Completed Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD)
Condition: Macular Degeneration
Interventions: Drug: Anecortave Acetate Sterile Suspension, 30 mg/mL;   Drug: Anecortave Acetate Sterile Suspension, 60 mg/mL;   Other: Anecortave Acetate Vehicle
11 Terminated A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD)
Condition: Macular Degeneration
Intervention: Drug: Pegaptanib sodium
12 Completed A Clinical Trial to Explore Safety and Efficacy of Different Doses of Pegaptanib Sodium, Compared to Sham, in Patients With Wet AMD.
Condition: Age-Related Macular Degeneration
Intervention: Drug: Pegaptanib sodium
13 Completed
Has Results
Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration Lesions
Condition: Macular Degeneration
Intervention: Drug: pegaptanib sodium (Macugen)
14 Recruiting Continuation of Previous Study to Gather More Data on Effect of Macugen on the Corneal Endothelium
Conditions: Age-Related Macular Degeneration;   Retinal Vein Occlusion;   Diabetic Macular Edema
Intervention: Drug: pegaptanib sodium injection
15 Completed Phase II/III Study of Anti-VEGF in Neovascular AMD
Conditions: Macular Degeneration;   Choroidal Neovascularization
Intervention: Drug: EYE001 anti-VEGF aptamer
16 Recruiting Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD
Condition: Visual Impairment Due to Neovascular AMD
Interventions: Drug: Ranibizumab;   Drug: Aflibercept
17 Completed
Has Results
A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.
Condition: Macular Edema Associated With Diabetes Mellitus
Interventions: Drug: Standard of Care;   Drug: Macugen
18 Completed
Has Results
Single Site, Masked, Randomized, Controlled Study to Assess Efficacy of Osurdex as Adjunct to Avastin Compared With Avastin Alone in the Treatment of Patients With Macular Edema Due to Central or Branch Retinal Vein Occlusion
Condition: Retinal Vein Occlusions
Interventions: Drug: Avastin;   Drug: Osurdex
19 Completed
Has Results
Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Branch Retinal Vein Occlusion (BRVO)
Conditions: Visual Impairment;   Macular Edema;   Branch Retinal Vein Occlusion
Interventions: Drug: Ranibizumab;   Other: Dexamethasone Implant;   Other: Sham injection
20 Completed Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Central Retinal Vein Occlusion (CRVO)
Conditions: Visual Impairment;   Macular Edema;   Central Retinal Vein Occlusion
Interventions: Drug: Ranibizumab;   Drug: Dexamethasone implant and sham injections

   Previous Page Studies Shown (1-20) Next Page (21-24) Show next page of results    Last Page
Indicates status has not been verified in more than two years